A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03.
Hitz, F
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. [electronic resource] - Hematological oncology Sep 2009 - 154-9 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
1099-1069
10.1002/hon.891 doi
Aged
Antimetabolites, Antineoplastic--adverse effects
Deoxycytidine--adverse effects
Disease Progression
Female
Humans
Lymphoma, Mantle-Cell--drug therapy
Male
Middle Aged
Recurrence
Remission Induction
Gemcitabine
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. [electronic resource] - Hematological oncology Sep 2009 - 154-9 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
1099-1069
10.1002/hon.891 doi
Aged
Antimetabolites, Antineoplastic--adverse effects
Deoxycytidine--adverse effects
Disease Progression
Female
Humans
Lymphoma, Mantle-Cell--drug therapy
Male
Middle Aged
Recurrence
Remission Induction
Gemcitabine